Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peng-Peng Xu

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Signal Transduction and Targeted Therapy|April 9, 2023
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaRong Shen, Di Fu, Lei Dong, et al.
Molecular Cancer|February 20, 2026
Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axisChen-Xing Zhao, Zi-Xun Yan, Jing-Jing Wen, et al.
Molecular Cancer|December 2, 2021
CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axisChen-Xing Zhao, Zi-Xun Yan, Jing-Jing Wen, et al.
Frontiers in Immunology|July 1, 2025
Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failureYing-Yu Dong, Qing Shi, Wen Wu, et al.
Biomarker Research|July 25, 2022
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphomaYu-Jia Huo, Peng-Peng Xu, Li Wang, et al.
Cell Communication and Signaling : CCS|December 23, 2025
XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axisTing-Ting Xu, Ming-Ci Cai, Shu Cheng, et al.
Signal Transduction and Targeted Therapy|July 27, 2025
Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)Yi-Ge Shen, Qing Shi, Wei Tang, et al.
Journal of Hematology & Oncology|October 2, 2014
Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradationLi Zhang, Qiu-Sheng Chen, Peng-Peng Xu, et al.
Ebiomedicine|October 24, 2017
A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-TypePeng-Peng Xu, Jie Xiong, Shu Cheng, et al.
Advances in Radiation Oncology|November 6, 2024
Treatment Outcomes and Prognostic Factors of Chemotherapy Combined With Radiation Therapy for Patients With Early-Stage Extranodal Natural Killer/T-Cell LymphomaShu-Bei Wang, Jia-Yi Chen, Wei-Li Zhao, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Signal Transduction and Targeted Therapy|April 9, 2023
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaRong Shen, Di Fu, Lei Dong, et al.
Molecular Cancer|February 20, 2026
Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axisChen-Xing Zhao, Zi-Xun Yan, Jing-Jing Wen, et al.
Molecular Cancer|December 2, 2021
CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axisChen-Xing Zhao, Zi-Xun Yan, Jing-Jing Wen, et al.
Frontiers in Immunology|July 1, 2025
Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failureYing-Yu Dong, Qing Shi, Wen Wu, et al.
Biomarker Research|July 25, 2022
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphomaYu-Jia Huo, Peng-Peng Xu, Li Wang, et al.
Cell Communication and Signaling : CCS|December 23, 2025
XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axisTing-Ting Xu, Ming-Ci Cai, Shu Cheng, et al.
Signal Transduction and Targeted Therapy|July 27, 2025
Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)Yi-Ge Shen, Qing Shi, Wei Tang, et al.
Journal of Hematology & Oncology|October 2, 2014
Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradationLi Zhang, Qiu-Sheng Chen, Peng-Peng Xu, et al.
Ebiomedicine|October 24, 2017
A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-TypePeng-Peng Xu, Jie Xiong, Shu Cheng, et al.
Advances in Radiation Oncology|November 6, 2024
Treatment Outcomes and Prognostic Factors of Chemotherapy Combined With Radiation Therapy for Patients With Early-Stage Extranodal Natural Killer/T-Cell LymphomaShu-Bei Wang, Jia-Yi Chen, Wei-Li Zhao, et al.
Pageof 9